Fmr LLC continued to hold its stake in Histogenics Corporation (NASDAQ:HSGX) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,729,620 shares of the biotechnology company’s stock at the end of the 2nd quarter. Fmr LLC owned 7.80% of Histogenics Corporation worth $3,113,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Shares of Histogenics Corporation (NASDAQ:HSGX) opened at $2.14 on Monday.

Histogenics Corporation (NASDAQ:HSGX) last issued its earnings results on Thursday, August 10th. The biotechnology company reported ($0.25) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.31) by $0.06. During the same quarter in the prior year, the business posted ($0.61) EPS. analysts predict that Histogenics Corporation will post -1.09 EPS for the current year.

A number of brokerages have recently issued reports on HSGX. HC Wainwright reissued a “buy” rating and issued a $3.50 price objective on shares of Histogenics Corporation in a research note on Thursday. Canaccord Genuity reissued a “buy” rating and issued a $4.00 price objective on shares of Histogenics Corporation in a research note on Friday, August 11th. ValuEngine cut shares of Histogenics Corporation from a “sell” rating to a “strong sell” rating in a research note on Monday, August 14th. Finally, Zacks Investment Research raised shares of Histogenics Corporation from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a research note on Tuesday, August 15th.

ILLEGAL ACTIVITY WARNING: This piece was first published by Watch List News and is the property of of Watch List News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://www.watchlistnews.com/fmr-llc-has-3113000-holdings-in-histogenics-corporation-hsgx/1682199.html.

About Histogenics Corporation

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

Want to see what other hedge funds are holding HSGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Histogenics Corporation (NASDAQ:HSGX).

Institutional Ownership by Quarter for Histogenics Corporation (NASDAQ:HSGX)

Receive News & Ratings for Histogenics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.